Compare BETR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | OMER |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.1M | 628.9M |
| IPO Year | N/A | 2009 |
| Metric | BETR | OMER |
|---|---|---|
| Price | $43.78 | $9.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 542.2K | ★ 1.7M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,545,000.00 | N/A |
| Revenue This Year | $53.90 | N/A |
| Revenue Next Year | $74.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.79 | N/A |
| 52 Week Low | $7.71 | $2.95 |
| 52 Week High | $94.06 | $13.60 |
| Indicator | BETR | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 63.77 |
| Support Level | $42.81 | $8.04 |
| Resistance Level | $48.89 | $10.41 |
| Average True Range (ATR) | 5.61 | 0.72 |
| MACD | -1.12 | 0.11 |
| Stochastic Oscillator | 11.42 | 78.06 |
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.